Background: The Food and Drug Administration mandates patient labeling materials like the Medication Guide (MG) and Instructions for Use (IFU) to support appropriate medication use. However, challenges such as low health literacy and difficulties navigating these materials may lead to incorrect medication usage, resulting in therapy failure or adverse outcomes. The rise of generative AI, presents an opportunity to provide scalable, personalized patient education through image recognition and text generation.
Objective: This study aimed to evaluate the accuracy and safety of medication instructions generated by ChatGPT based on user-provided drug images, compared to the manufacturer's standard instructions.
Methods: Images of 12 medications requiring multiple steps for administration were uploaded to ChatGPT's image recognition function. ChatGPT's responses were compared to the official IFU and MG using text classifiers, Count Vectorization (CountVec), and Term Frequency-Inverse Document Frequency (TF-IDF). The clinical accuracy was further evaluated by independent pharmacists to determine if ChatGPT responses were valid for patient instruction.
Results: ChatGPT correctly identified all medications and generated patient instructions. CountVec outperformed TF-IDF in text similarity analysis, with an average similarity score of 76%. However, clinical evaluation revealed significant gaps in the instructions, particularly for complex administration routes, where ChatGPT's guidance lacked essential details, leading to lower clinical accuracy scores.
Conclusion: While ChatGPT shows promise in generating patient-friendly medication instructions, its effectiveness varies based on the complexity of the medication. The findings underscore the need for further refinement and clinical oversight to ensure the safety and accuracy of AI-generated medical guidance, particularly for medications with complex administration processes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.japh.2024.102284 | DOI Listing |
Alzheimers Dement
December 2024
Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
In Japan, the regulatory authority approved the drug in September 2023, and on December 20, it became available for prescription country-wide under the health insurance system. However, there are strict patient, physician, and facility requirements for the prescription of Lecanemab, and various problems are anticipated in its future implementation and widespread use in society. Lecanemab is the first anti-Aβ antibody in Japan, and even dementia specialists do not have sufficient knowledge and experience in its introduction, evaluation of efficacy, and evaluation and handling of side effects.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California, Irvine, Irvine, CA, USA.
Background: Recruitment challenges in people with and without Down syndrome (DS) can delay research progress and risk sample bias. This study identified and quantified differences in research attitudes across populations of research enrollment decision-makers for individuals with and without DS.
Method: We compared scores on the Research Attitudes Questionnaire (RAQ) of individuals enrolled in two recruitment registries: the UCI Consent to Contact [C2C (N = 4818)] and DS-Connect (N = 976).
Alzheimers Dement
December 2024
Johns Hopkins Global Neurology, University Teaching Hospital, Lusaka, Lusaka, Zambia.
Background: Globally, 47.5 million people were living with dementia in 2015. This figure is expected to reach 75.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Neuroscience and Aging Research Unit, Institute of Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Background: Historically, efforts to engage under-represented communities in health research have encountered limited success, attributable to inadequate community participation, acceptability, and ownership. Globally, an innovative strategy to foster community involvement in research is the establishment of Community Advisory Boards (CABs). These boards consist of stakeholders from the target community, providing partnership and support throughout all phases of the research, from conception to implementation and evaluation.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
UMass Chan Medical School, Worcester, MA, USA.
Background: Almost all primary care providers (PCPs) believe screening for mild cognitive impairment (MCI) and dementia in older patients is important. However, there are significant barriers in primary care, including low provider confidence in their assessment skills, time constraints, competing priorities, and poor financial incentives. Consequently, PCPs report conducting cognitive assessments for less than half of patients over 60 years of age.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!